You learned the two cardinal symptoms of major depressive disorder in your very first psychiatry lecture: depressed mood and loss of interest or pleasure. You memorized them for boards. You ask about them every shift in clinical. And then, somewhere along the way, “loss of interest or pleasure” quietly got demoted in your head to a checkbox.
Here’s the uncomfortable truth: that checkbox is the symptom your first-line antidepressants probably aren’t fixing. And it’s also the symptom most strongly linked to suicidal behavior, longer episodes, and patients who tell you “I’m fine, the medication is working” while their lives keep getting smaller.
The clinical name is anhedonia — the reduced ability to anticipate, pursue, and feel pleasure. It is having a moment in psychiatry right now, and as a future PMHNP, you need to understand why. Three major stories from the last twelve months are converging on the same conclusion: we have to stop treating anhedonia as a side note and start treating it as a primary target.
Let’s walk through what’s changing, why it’s on your boards in everything but name, and what you can actually do about it on day one of practice.
Why Anhedonia Quietly Outranks Sadness
Anhedonia is one of the two gate criteria for MDD in the DSM-5-TR. A patient needs depressed mood or diminished interest/pleasure plus four additional symptoms for two weeks. That “or” matters: a patient with profound anhedonia and no overt sadness still meets full criteria. Many do. They tell you they feel “flat,” “numb,” “empty,” or “just going through the motions.” They are not necessarily crying. They are not necessarily saying they want to die. But they are sick.
Psychiatric Times has spent the last two years making the case that anhedonia is woefully underrecognized and undertreated in major depression. Their clinical reviews put the prevalence in depressed patients at nearly 90% and link the symptom to longer time-to-remission, higher relapse risk, more disability, and increased suicide risk. Anhedonia also appears in PTSD, schizophrenia, substance use disorders, and anxiety disorders — meaning the diagnostic framework you build around it is portable across your entire patient panel.
The reason this matters for your prescribing pad is that anhedonia maps onto a different brain system than sadness. Sadness lives heavily in the serotonergic/limbic circuitry that SSRIs were designed for. Anhedonia, by contrast, is a reward-system problem — dopaminergic projections from the ventral tegmental area into the nucleus accumbens and prefrontal cortex, plus interaction with the kappa-opioid system. That’s why patients can have their PHQ-9 drop from 22 to 12, declare themselves “better,” and still tell you food has no taste and they can’t remember the last time they enjoyed their kid’s soccer game.
If you only chase total scores, you will miss them.

Story One: Cariprazine and the 26-Week Anhedonia Signal
At the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Scottsdale in 2025, investigators presented long-term, open-label data on adjunctive cariprazine in patients with major depressive disorder and significant anhedonia. The headline finding, reported in Psychiatric Times, was a sustained reduction in anhedonia subscale scores that appeared by week 4 and held through week 26. The most common effective dose was 3 mg/day, with 1.5 mg and 4.5 mg as common alternates.
Why does this matter? Cariprazine is a partial agonist at D3 and D2 receptors, with preferential D3 activity. D3 receptors cluster in the limbic reward circuitry — exactly the territory where standard SSRIs barely show up. The drug has been FDA-approved as adjunctive treatment for MDD since December 2022, but the anhedonia-specific data is what is changing how seasoned prescribers use it. Instead of reaching for cariprazine only after multiple failed augmentation strategies, more clinicians are reaching for it earlier when the dominant residual symptom is “I just can’t feel anything good.”
For boards: know that cariprazine’s mechanism is D3-preferring partial agonism, that it’s approved for schizophrenia, bipolar I (manic, depressed, and mixed), and adjunctive MDD, and that long-term tolerability is dominated by akathisia and extrapyramidal symptoms — both dose-dependent. You should also know it has a long half-life (the active metabolite didesmethylcariprazine sits around 1–3 weeks), so titration is slow and washout is slower.
Story Two: The Aticaprant Failure That Still Teaches You Something
For a few years, the kappa-opioid receptor (KOR) was the most-watched novel target in depression research. The theory was elegant: dynorphin, the endogenous KOR agonist, suppresses dopamine release in the reward pathway. Block KOR, and you should restore reward processing — directly attacking anhedonia.
Aticaprant, a selective KOR antagonist that Johnson & Johnson acquired from Cerecor (originally Lilly), made it all the way to Phase 3 as an adjunctive treatment for MDD with moderate-to-severe anhedonia. Then in March 2025, J&J announced that the program failed to meet its primary efficacy endpoint and discontinued development for MDD. Coverage in industry pipeline trackers confirmed the trial did not separate from placebo.
So why are we still talking about it? Two reasons. First, the mechanistic story isn’t dead — other KOR antagonists and dual-action compounds are still in development, and the underlying neurobiology of the dynorphin/KOR system in stress-induced anhedonia is still considered clinically important. Second, the aticaprant story is a perfect case study in why “biologically plausible” doesn’t mean “clinically effective.” Your patients will not benefit from a drug that signals at the right receptor if the downstream behavior doesn’t change.
Make that lesson stick. You’ll see it again with the next novel target.
Story Three: Positive Affect Treatment Outperforms Standard CBT
Now the most underappreciated story of the bunch. In a 2026 randomized clinical trial reported in JAMA Network Open, researchers led by Michelle Craske at UCLA, with Alicia Meuret and Thomas Ritz at SMU, tested a 15-session psychotherapy called Positive Affect Treatment (PAT) head-to-head against a more conventional protocol aimed at reducing negative affect. Ninety-eight adults with severe anhedonia, depression, and anxiety were randomized.
The PAT group outperformed standard treatment on overall clinical status. They also showed significant reductions in depression and anxiety scores — even though PAT never directly targeted negativity. The researchers attribute the effect to direct modulation of reward and threat processing through behavioral activation, cognitive amplification of positive experiences, and experiential savoring practices.
The implication is enormous. We have spent decades building therapy protocols designed to subtract negative emotion. PAT suggests that adding positive emotion may be a more powerful lever for a meaningful subset of patients — particularly those whose depression looks more like “the lights are off” than “I am crushed by sadness.” For PMHNPs who refer for therapy or co-manage with a therapist, this is a referral pattern worth knowing by name.
None of this means CBT is obsolete. It means anhedonia-dominant patients may need a different kind of psychotherapy partner — and you should ask your referral network whether anyone is trained in PAT, behavioral activation for anhedonia, or related reward-focused protocols.

How to Actually Assess Anhedonia in Clinic
You can do this in under three minutes. Two validated tools dominate the literature.
The Snaith-Hamilton Pleasure Scale (SHAPS) is 14 items, takes about two minutes, and asks the patient to rate agreement with statements like “I would enjoy a warm bath or refreshing shower” or “I would find pleasure in my hobbies and pastimes.” It assesses consummatory pleasure — the part of reward that happens in the moment. Higher scores indicate more anhedonia. It’s the workhorse for quick clinical screening.
The Dimensional Anhedonia Rating Scale (DARS) goes deeper. It captures anticipatory, motivational, and consummatory anhedonia across personalized domains — hobbies, sensory experiences, social interactions, and food. A 2025 study in the Journal of Psychiatric Research found that DARS explains substantially more variance in anhedonia than SHAPS (73% versus 48%) and is better at detecting subtle hedonic deficits. Use it when SHAPS feels too blunt — particularly for patients in partial remission who keep telling you “something still isn’t right.”
The clinical move that separates competent prescribers from great ones is this: do not collapse anhedonia into the PHQ-9 item about “little interest or pleasure.” That single item is a screen, not a measurement. Use SHAPS or DARS at intake, again at 4–6 weeks, and again whenever a patient says they feel “better but not better.”
Putting It Together: A Practical Algorithm
Once you’ve identified clinically significant anhedonia, the menu of options looks something like this, with the caveat that you should always individualize.
For a patient on a maximally tolerated SSRI or SNRI with residual anhedonia, the Carlat Psychiatry Report has consistently raised pramipexole as an underused augmentation strategy — Chris Aiken and Kellie Newsome have written and podcasted repeatedly about it as a dopamine-agonist option for anhedonic depression, with the caveat of nausea, impulse control disorders, and a slow titration. Bupropion remains an obvious add-on or switch given its dopaminergic and noradrenergic activity — and it is one of the antidepressants with the most consistent signal in anhedonia-dominant phenotypes.
Cariprazine, as discussed, has the most recent and most specific anhedonia data and is FDA-approved adjunctive for MDD. Aripiprazole remains in the same general space, though without the cleaner D3-preferring profile. Lower-dose aripiprazole (2–5 mg) is still the augmentation strategy with the largest evidence base behind it.
On the psychotherapy side, refer to behavioral activation, Positive Affect Treatment if you can find a clinician trained in it, or any structured anhedonia-targeted protocol — savoring practices, structured reward scheduling, gratitude work integrated with values-based action. Generic supportive therapy will not move the needle.
Consider measurement-based care a non-negotiable. Anhedonia is the symptom you will miss most often without a scale — and the symptom that, when missed, contributes most to the patients who quietly slip from “stable” to “hospitalized.”
What This Means for Your Boards and Your Practice
The ANCC and AANP psychiatric-mental health nurse practitioner board blueprints will not ask you to recite the PAT protocol or the aticaprant Phase 3 result. They will, however, expect you to know the DSM-5-TR criteria for MDD cold (including anhedonia as a gate criterion), to identify residual symptoms in a treated depression vignette, to choose appropriate augmentation strategies, and to recognize that suicide risk does not move in lockstep with mood — it moves with hopelessness, agitation, and yes, anhedonia.
The patient in the test question who tells you “I’m fine, the medication is working” while reporting weight loss, social withdrawal, and “I just don’t feel anything anymore” is the patient whose treatment isn’t done. You need to recognize that, name it as anhedonia, and choose the next step.
And the patient in your actual clinic who tells you the same thing? They need the same recognition. They need you to ask the second question — “What did you used to enjoy that you don’t enjoy now?” — and the third — “When was the last time something genuinely felt good?” The answers will tell you what your scales confirm.
You are training to be the kind of clinician who notices when a patient has improved on paper but not in life. That noticing is what good psychiatric care looks like. The science of anhedonia is finally catching up to what experienced clinicians have always known: depression is not one symptom you treat with one drug. It’s a constellation, and the dimmest stars are sometimes the ones that decide whether a patient comes back next month.
Keep learning. Keep asking the second question. And the next time a patient tells you they’re “fine” with a flat affect and a half-eaten lunch, reach for SHAPS instead of relief.
Ready to sharpen the clinical reasoning skills that show up on every PMHNP board question? PMHNPReview.org walks you through high-yield psychopharmacology, diagnosis vignettes, and the exact pattern recognition your boards are testing for.
